Results from a phase III COVID-19 study showed that oral sabizabulin, a novel dual antiviral and anti-inflammatory agent, improved outcomes in hospitalized moderate-to-severe COVID-19 patients at high risk for acute respiratory distress syndrome and death.
Radiology departments have tried for years to “own” or “fix” clinical trials imaging assessment workflows by extending clinical tools (PACS, worklists, dictation systems) and habits (speed, seamlessness, few clicks) into the research world.
